J&J expects data for U.S. authorization of COVID-19 vaccine by Feb, says head scientist

(Reuters) - Johnson & Johnson's chief scientist said the drugmaker is recruiting over 1,000 people per day for the late-stage trial of its experimental COVID-19 vaccine and expects to have all the data needed to seek U.S. authorization by February or earlier. 'By the end of the year or around the end of the year, we should have 60,000 people in the study,' Dr

Reuters November 18, 2020 02:11:26 IST
J&J expects data for U.S. authorization of COVID-19 vaccine by Feb, says head scientist

COVID-19 vaccine by Feb, says head scientist" src="https://images.firstpost.com/wp-content/uploads/reuters/11-2020/18/2020-11-17T194648Z_1_LYNXMPEGAG1NO_RTROPTP_2_HEALTH-CORONAVIRUS-VACCINE.jpg" alt="JJ expects data for US authorization of COVID19 vaccine by Feb says head scientist" width="300" height="225" />

(Reuters) - Johnson & Johnson's chief scientist said the drugmaker is recruiting over 1,000 people per day for the late-stage trial of its experimental COVID-19 vaccine and expects to have all the data needed to seek U.S. authorization by February or earlier.

"By the end of the year or around the end of the year, we should have 60,000 people in the study," Dr. Paul Stoffels, J&J's chief scientific officer, said in an interview ahead of this week's Reuters Total Health conference.

"And efficacy endpoint should be there in the first few weeks or months, January or February, of the new year," he added.

The Phase III trial of the single-dose vaccine started in late September. The company paused the trial in October because of a serious medical event in one participant and resumed after getting the green light from an independent safety panel.

J&J must provide safety data to the U.S. Food and Drug Administration for at least one-half of trial participants for a duration of two months after they receive the vaccine. "So that will bring us around the year end or early next year for having all the data," he added.

J&J lags some of its rivals in the global race to develop a safe and effective vaccine against the virus that has killed over 1.3 million people worldwide and roiled the global economy.

Rival Moderna on Monday said its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage clinical trial, following similar results from Pfizer last week.

Both Pfizer's and Moderna's vaccines use a new technology known as messenger RNA, or mRNA. By contrast, J&J's vaccine uses a common cold virus known as adenovirus type 26 to introduce coronavirus proteins into cells in the body and trigger the body's immune system.

J&J's candidate is a single-dose vaccine, whereas the vaccines from Moderna and Pfizer and another under development by AstraZeneca all require two shots separated by several weeks.

"In a pandemic a single shot is definitely important globally," Stoffels said. "(A two-shot vaccine) is a very significant operational challenge. More so in healthcare systems which are less well organized."

Single-shot vaccines will likely benefit in particular remote areas, Stoffels said.

For more on Reuters Events Total Health click here: https://reutersevents.com/events/healthcare/

(Reporting by Manojna Maddipatla in Bengaluru and Axel Threlfall in London; Editing by Bill Berkrot and Rosalba O'Brien)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

France reports 35,879 new coronavirus cases, overtakes Russia
World

France reports 35,879 new coronavirus cases, overtakes Russia

By Shaina Ahluwalia and Geert De Clercq PARIS (Reuters) - France reported 35,879 new coronavirus cases on Wednesday, taking the total to 1.86 million, overtaking Russia and making France the worst affected country in the European region. With a total of 1,865,538 confirmed cases, France is the fourth-worst affected country in the world for novel coronavirus infections, according to a Reuters tally.

Hong Kong pro-democracy lawmakers to resign as Beijing moves to quash opposition
World

Hong Kong pro-democracy lawmakers to resign as Beijing moves to quash opposition

By Jessie Pang and Sharon Tam HONG KONG (Reuters) - Hong Kong's pro-democracy opposition lawmakers said on Wednesday they would resign in protest against the dismissal of four of their colleagues from the city assembly after Beijing gave local authorities new powers to further curb dissent. The Chinese parliament earlier adopted a resolution allowing the city's executive to expel lawmakers deemed to be advocating Hong Kong independence, colluding with foreign forces or threatening national security, without having to go through the courts

Chile accuses Colombian man in serial killings of homeless people
World

Chile accuses Colombian man in serial killings of homeless people

SANTIAGO (Reuters) - Chilean authorities have accused a Colombian man of murdering at least seven people, including several who were homeless on the streets of the capital Santiago. Police arrested Diego Ruiz Restrepo, 30, on Monday after using surveillance camera images to identify him, the regional prosecutor's office said on Twitter.